Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment- naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial

被引：1
|
作者：
Procopio, Giuseppe
Verzoni, Elena
Bracarda, Sergio
Ricci, Sergio
Ridolfi, Laura
Sacco, Cosimo
Miceli, Rosalba
Porta, Camillo
Bregni, Marco
Bajetta, Emilio
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Osped San Donato, Dept Oncol, USL 8, Arezzo, Italy
[3] Osped Santa Chiara, Pisa, Italy
[4] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[5] Univ Hosp Udine, Udine, Italy
[6] Univ San Matteo, Fdn IRCCS Policlin, Pavia, Italy
[7] Osped Busto Arsizio, Busto Arsizio, Italy
[8] Policlin Monza, Ist Oncol, Monza, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.356
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
356
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A RANDOMIZED, PROSPECTIVE, PHASE 2 STUDY, WITH SORAFENIB (S) AND INTERLEUKIN-2 (IL-2) VERSUS S ALONE AS FIRST LINE TREATMENT IN ADVANCED RENAL CELL CANCER (RCC): ROSORC TRIAL
    Procopio, Giuseppe
    Verzoni, Elena
    Bracarda, Sergio
    Ricci, Sergio
    Bregni, Marco
    Conti, Giario N.
    Amoroso, Vito
    Sacco, Cosimo
    Zilembo, Nicoletta
    Bajetta, Emilio
    ANNALS OF ONCOLOGY, 2009, 20
  • [12] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2)
    Parikh, Kinjal
    Stenehjem, David D.
    Sendilnathan, Arun
    Crispin, Hilda
    Van Atta, Joan
    Batten, Julia Anne
    Sageser, Daniel
    Grossmann, Kenneth F.
    Wang, Junfeng
    Samlowski, Wolfram E.
    Tantravahi, Srinivas Kiran
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [13] A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)
    Garcia, J. A.
    Rini, B. I.
    Mekhail, T.
    Triozzi, P.
    Elson, P.
    Nemec, C.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [14] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2)
    Straubhar, Alli M.
    Stenehjem, David D.
    Parikh, Kinjal
    Merriman, Joseph
    Crispin, Hilda
    Sendlinathan, Arun
    Van Atta, Joan
    Batten, Julia A.
    Agarwal, Archana M.
    Tantravahi, Srinivas Kiran
    Samiowski, Wolfram E.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [15] Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2)
    Huland, E
    Heinzer, H
    Huland, H
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2679 - 2683
  • [16] Efficacy of gabapentin on pruritus induced by interleukin-2 (IL-2) treatment in patients with metastatic renal cell carcinoma and melanoma
    Lee, S.
    Rusciano, V.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [17] Subcutaneous (sc) interleukin-2 (IL-2) plus alpha-interferon (IFNα) in out-patients (pts) with metastatic renal cell carcinoma (MRCC).: SCAPP III trial.
    Tourani, JM
    Pfister, C
    Tubiana, N
    Rixe, O
    Benoit, G
    Mayeur, D
    Lucas, V
    Prevot, G
    Untereiner, M
    Favre, R
    ANNALS OF ONCOLOGY, 2000, 11 : 75 - 75
  • [18] OVERALL SURVIVAL (OS) IN METASTATIC RENAL CELL CARCINOMA (MRCC): A COMPARISON BETWEEN SORAFENIB (SO) AND BEST SUPPORTIVE CARE (BSC) AFTER FIRST LINE TREATMENT WITH SUNITINIB (SU) IN SWEDEN
    Sandstrom, P.
    Sandin, R.
    Kowalski, J.
    Wahlgren, T.
    Jakobsson, M.
    Lundstam, S.
    Ljungberg, B.
    Harmenberg, U.
    ANNALS OF ONCOLOGY, 2012, 23 : 281 - 281
  • [19] SUBGROUP ANALYSIS AND UPDATED RESULTS OF A RANDOMIZED STUDY COMPARING SORAFENIB PLUS INTERLEUKIN-2 VERSUS SORAFENIB ALONE AS FIRST-LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA
    Procopio, Giuseppe
    Verzoni, Elena
    Bracarda, Sergio
    Conti, Giario
    Guadalupi, Valentina
    Ortega, Cinzia
    Nicolai, Nicola
    Torelli, Tullio
    Bajetta, Emilio
    Salvioni, Roberto
    ANTICANCER RESEARCH, 2010, 30 (04) : 1461 - 1462
  • [20] Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIM HD IL-2 National Registry
    Clark, Joseph
    Morse, Michael
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Hua, Hong
    Aung, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345